• Tamoxifen Enhances Radiotherapy via Macrophage M1 Polarizati

  2026-07-31

  A recent study demonstrates that high-dose tamoxifen acts as a potent immunomodulator, promoting M1 polarization of tumor-associated macrophages (TAMs) and enhancing the efficacy of radiotherapy through JNK/c-JUN activation. These findings suggest a new mechanism for tamoxifen beyond estrogen receptor antagonism, with practical implications for combination cancer therapies in both ER-positive and ER-negative tumors.

• Targeting BCL-XL in Glioblastoma: Insights from Apoptotic Se

  2026-07-31

  The referenced study elucidates how glioblastoma (GBM) cells, particularly stem-like subpopulations, display elevated expression of anti-apoptotic BCL-XL and MCL-1. This heightened apoptotic priming renders GBM susceptible to BH3-mimetic therapy targeting BCL-2 family proteins. The findings provide a rationale for selective BCL-XL inhibition in apoptosis assays and cancer research, highlighting translational potential for improved therapeutic strategies.

• Ruxolitinib Phosphate: Unraveling JAK/STAT Modulation in Agg

  2026-07-30

  Explore how Ruxolitinib phosphate (INCB018424) advances JAK/STAT pathway modulation research, with a unique focus on mitochondrial dynamics and apoptosis in aggressive solid tumors. This article provides in-depth analysis and practical assay guidance beyond conventional protocols.

• Tofacitinib (CP-690550): Repairing Inflammation and Metaboli

  2026-07-30

  This article explores the mechanistic and translational importance of Tofacitinib (CP-690550) in modulating GM-CSF-driven inflammation and mitochondrial dysfunction in rheumatoid arthritis. By integrating recent evidence, strategic workflow recommendations, and APExBIO’s product expertise, we outline how translational researchers can leverage this JAK inhibitor to design assays that dissect immune-metabolic crosstalk and advance precision immunomodulation.

• Tumor-Targeted Heptamethine Cyanine Dye in HR+ Breast Cancer

  2026-07-29

  A recent study introduces CA800-PR, a hydrophilic heptamethine cyanine dye, as a novel agent that selectively suppresses progesterone receptor activity and induces Golgi fragmentation in hormone receptor-positive breast cancer. This work demonstrates the potential of dye-based tumor targeting to provide both imaging and direct antitumor effects, suggesting alternatives to conventional hormone therapies.

• LMP2A-mTORC1-GCNT3 Axis Drives EMT in Nasopharyngeal Carcino

  2026-07-29

  This study uncovers how Epstein-Barr virus (EBV) latent membrane protein 2A (LMP2A) upregulates GCNT3 via the mTORC1 pathway in nasopharyngeal carcinoma (NPC), promoting cell proliferation and epithelial-mesenchymal transition (EMT). The findings reveal a positive feedback between mTORC1 and GCNT3, highlighting the axis as a promising target for NPC research and therapeutic intervention.

• Ciprofloxacin (hydrochloride): Workflow-Ready Solutions for

  2026-07-28

  This scenario-driven guide details how Ciprofloxacin (hydrochloride) (SKU C5539) streamlines cell viability, proliferation, and cytotoxicity workflows for biomedical researchers. Drawing from current literature and validated protocols, it addresses common laboratory challenges—ensuring reproducibility, compatibility, and confidence in results. APExBIO’s C5539 is highlighted for its purity, solubility, and applicability across antibacterial and immunomodulatory research.

• Disulfiram in Synthetic Lethality: Precision Strategies for

  2026-07-28

  Explore how Disulfiram, a dopamine β-hydroxylase inhibitor, enables targeted synthetic lethality in APC-deficient cancer models. This article delivers a unique, evidence-driven guide to leveraging Disulfiram’s multi-modal mechanisms and protocol optimization for advanced cancer research.

• Ruxolitinib Phosphate: Unveiling New Mechanisms in Cancer Re

  2026-07-27

  Explore the unique role of Ruxolitinib phosphate in JAK/STAT signaling pathway modulation for advanced cancer and autoimmune disease research. This article delivers a deep dive into recent mechanistic discoveries, practical assay implications, and expert guidance distinct from standard protocol-focused resources.

• SAR131675 and VEGFR-3 Inhibition: Pathway Dissection Beyond

  2026-07-27

  Explore how SAR131675, a selective VEGFR-3 inhibitor, uniquely advances pathway dissection in liver fibrosis and immune modulation beyond its established roles in oncology. Discover protocol insights and novel translational perspectives anchored in recent mechanistic studies.

• TRIM66 Controls Monogenic Olfactory Receptor Expression via

  2026-07-26

  This study identifies TRIM66 as a crucial epigenetic repressor governing the monogenic expression of olfactory receptors in sensory neurons. By elucidating TRIM66’s role in silencing all but one receptor gene per neuron, the work clarifies a longstanding question in sensory neurobiology and offers a framework for dissecting stochastic gene regulation in complex tissues.

• Gli1+ Progenitors Drive Glucocorticoid-Induced Osteoporosis

  2026-07-25

  Yang et al. reveal that Gli1+ metaphyseal mesenchymal progenitors (MMPs) are key mediators of glucocorticoid-induced osteoporosis in vivo. Their lineage tracing and single-cell RNA sequencing approaches clarify the target cell population and metabolic disruptions underlying bone loss, with direct implications for osteoporosis treatment strategies.

• 3X (DYKDDDDK) Peptide: Structural Biology and Metal-Dependen

  2026-07-24

  Explore the unique role of the 3X (DYKDDDDK) Peptide in structural biology, with a focus on metal-dependent mechanisms and advanced purification strategies. This article reveals how the 3X FLAG peptide enables next-generation affinity workflows beyond standard protocols.

• Imidazoline Antagonists Enhance Insulin Release via K+ Chann

  2026-07-24

  This study demonstrates that imidazoline antagonists of α2-adrenoceptors increase insulin secretion from pancreatic β-cells in vitro, not by receptor antagonism, but by inhibiting ATP-sensitive potassium channels. The findings clarify a non-adrenergic mechanism relevant to diabetes research and highlight experimental approaches to dissect K+ channel function in metabolic regulation.

• Applied Workflows for BCL-XL Inhibitor A-1155463 in Cancer R

  2026-07-23

  Unlock the full potential of A-1155463, a selective BCL-XL inhibitor, for precision apoptosis induction in resistant cancer models. This article delivers practical protocols, troubleshooting strategies, and research-backed insights, directly linking advanced lab workflows to breakthrough findings in tumor biology.

14901 records 1/994 page Next 12345 下5页 Last page